Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast Cancer
Cancer Research and Treatment. 2006;38(1):35 
HER2-positive metastatic breast cancer: second-line treatment
Handbook of HER2-Targeted Agents in Breast Cancer. 2016;71-86
HER2-positive metastatic breast cancer: first-line treatment
Handbook of HER2-Targeted Agents in Breast Cancer. 2016;51-69
Emerging targeted agents for HER2-positive breast cancer
Handbook of HER2-Targeted Agents in Breast Cancer. 2016;87-110
HER2-positive breast cancer: neoadjuvant and adjuvant therapy
Handbook of HER2-Targeted Agents in Breast Cancer. 2016;29-49
First-Line Efficacy of Anti-HER2 Treatments in Previously Treated HER2-Positive Metastatic Breast Cancer Patients: A Retrospective Observational Study Investigating the Efficacy of Re-Exposure to Anti-HER2 Therapy for HER2-Positive Metastatic Breast Cancer Patients in Comparison with Naïve Patients
Breast Care. 2021;1-7
HER2-Positive Breast Cancer
Her2-Positive Breast Cancer. 2019;63-74
1–33 Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer
Breast Diseases: A Year Book Quarterly. 2007;18(1):63-64
Biosimilars for HER2-Positive Breast Cancer
Her2-Positive Breast Cancer. 2019;231-237
PO141 SUCCESSFUL USE OF HER2 TARGETED AGENTS IN PATIENTS WITH HEAVILY PRETREATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTING WITH ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN AND/OR HER2 OVEREXPRESSING CIRCULATING TUMOR CELLS
The Breast. 2015;24:S70